TAEUS Liver Device Demonstrates Clinical-Grade Consistency in Multi-Operator Study; NDRA Stock Shows Recovery

ENDRA Life Sciences Inc. (NDRA) has released significant clinical validation data showing that its TAEUS Liver device achieves remarkable consistency in real-world diagnostic settings. The breakthrough consistency metrics suggest the technology could reshape how healthcare providers approach liver fat monitoring in clinical practice.

Clinical Data Validates TAEUS Performance with Strong Reproducibility

The clinical study enrolled 14 subjects and generated 56 separate measurements performed by different medical operators to rigorously test the device’s reproducibility. Results demonstrated that TAEUS achieved an intraclass correlation coefficient (ICC) of 0.89—a statistical benchmark considered “good to excellent” in medical research standards. This level of consistency is particularly noteworthy because it was maintained even when multiple clinicians performed the scanning procedures independently, without operator-specific training variations affecting the outcomes.

The device registered a low standard error of measurement at just 3.3%, indicating that readings remained remarkably stable across different users. This operator-independent performance is a critical advantage, as consistency across multiple clinicians is essential for widespread clinical adoption and regulatory approval.

Why Operator Consistency Matters for Point-of-Care Diagnostics

The consistency advantage directly addresses a long-standing limitation of traditional ultrasound-based liver assessment, which frequently shows significant variation depending on which technician or radiologist performs the scan. ENDRA positioned TAEUS as capable of delivering MRI-equivalent consistency—while MRI remains the gold standard for liver fat quantification, it suffers from accessibility challenges and substantial costs that limit routine clinical use.

TAEUS bridges this gap by offering precision comparable to MRI while maintaining the speed, accessibility, and affordability of point-of-care ultrasound technology. For patients with metabolic dysfunction-associated steatotic liver disease (MASLD), a condition affecting approximately 30% of the global adult population, this consistency could enable more frequent monitoring and better therapeutic outcomes.

Market Opportunity and Clinical Application Potential

The consistency data opens multiple commercial pathways. Beyond routine patient monitoring, ENDRA highlighted potential applications in pharmaceutical clinical trials, where consistent liver fat measurements would streamline patient recruitment, baseline assessment, and longitudinal follow-up protocols. Pharmaceutical companies conducting liver disease research could significantly reduce measurement variability and accelerate trial timelines.

The device’s reliability also supports ongoing clinical care in metabolic disease management, gastroenterology, and hepatology practices, where objective, operator-independent liver fat quantification could become standard protocol.

NDRA Stock Position and Investment Indicators

NDRA has traded within a range of $2.90 to $11.96 over the trailing twelve months, reflecting the typical volatility of early-stage medical device companies. The stock currently trades at $4, up 7% from recent lows, suggesting modest investor response to the clinical validation announcement. The consistency data and broadening clinical applications provide a tangible asset story for the company moving forward.